secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ayala Pharmaceuticals, Inc. (—)
CIK:        0001100397
Form:       8-K
Filed at:   2023-04-07T23:59:59+00:00
Accession:  0001493152-23-011596
Event type: other
Sentiment:  neutral
Materiality: 0.35
Item codes: 4.01
LLM model:  deepseek-v4-flash:cloud@v2

Ayala Pharmaceuticals dismisses Marcum as auditor, engages KFGK for FY 2023
---------------------------------------------------------------------------

- Audit committee discontinued Marcum engagement on April 5, 2023; no disagreements with Marcum.
- Marcum's audit reports for FY ended Oct 2022 and 2021 included a going concern explanatory paragraph.
- KFGK (Kost, Forer, Gabbay & Kasierer, member of EY Global) engaged to audit FY ending Dec 31, 2023.
- Change follows reverse merger where Old Ayala is accounting acquirer; KFGK previously audited Old Ayala's 2022/2021 financials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100397/000149315223011596/0001493152-23-011596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100397/000149315223011596/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-011596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer